<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIA</journal-id>
<journal-id journal-id-type="hwp">spjia</journal-id>
<journal-id journal-id-type="nlm-ta">J Int Assoc Physicians AIDS Care (Chic Ill)</journal-id>
<journal-title>Journal of the International Association of Physicians in AIDS Care</journal-title>
<issn pub-type="ppub">1545-1097</issn>
<issn pub-type="epub">1557-0886</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1545109711427606</article-id>
<article-id pub-id-type="publisher-id">10.1177_1545109711427606</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Low Prevalence of Chronic Hypertransaminasemia in a Cohort of HIV-Infected Patients with No Coinfections</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pérez</surname>
<given-names>Isabel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1545109711427606">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López</surname>
<given-names>Antonio</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1545109711427606">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Palacios</surname>
<given-names>Rosario</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1545109711427606">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Santos</surname>
<given-names>Jesús</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1545109711427606">1</xref>
<xref ref-type="corresp" rid="corresp1-1545109711427606"/>
</contrib>
</contrib-group>
<aff id="aff1-1545109711427606">
<label>1</label>Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Virgen de la Victoria, Málaga, Spain</aff>
<author-notes>
<corresp id="corresp1-1545109711427606">Jesús Santos, MD, PhD, Unidad de Gestión Clínica de Enfermedades Infecciosas, Campus Teatinos s/n, Hospital Virgen de la Victoria, Málaga 29010, Spain Email: <email>med000854@saludalia.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>11</volume>
<issue>2</issue>
<fpage>89</fpage>
<lpage>90</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<kwd-group>
<kwd>hypertransaminasemia</kwd>
<kwd>liver disease</kwd>
<kwd>non-alcoholic fatty liver disease</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>March/April 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Liver disease is very common in patients with HIV infection.<sup>
<xref ref-type="bibr" rid="bibr1-1545109711427606">1</xref>
</sup> The association between chronic infection with hepatotropic viruses and being a target for other diseases, such as opportunistic infections and tumors, nonalcoholic fatty liver disease (NAFLD), and toxicity to drugs, including antiretroviral therapy (ART), results in liver disease being a leading cause of morbidity and mortality in these persons.<sup>
<xref ref-type="bibr" rid="bibr1-1545109711427606">1</xref>
</sup>
</p>
<p>The aim of this study was to determine the prevalence of chronic hypertransaminasemia (CHT) in a cohort of patients with HIV infection but no coinfection and to examine the factors associated with CHT.</p>
<p>We undertook a cross-sectional, case-control study of all HIV-infected patients who regularly attended the infectious diseases office of our center from March to August 2009. A case was defined as any patient with glutamate pyruvate transaminase (GPT) values above normal (78 IU/L) at least 2 consecutive revisions (3 months or more between the 2 measurements). Patients were excluded if they had a positive serology to a hepatotropic virus or opportunistic events during the previous month. A control was defined as a patient attending the office paired for age (±5 years) and sex with a case and who had a normal GPT value, using the same exclusion criteria as for the cases. Hepatotoxicity of ART was defined as CHT due to ART, and to make this diagnosis, other causes of elevated GPT values were ruled out in all cases and NAFLD by the presence of steatosis in an abdominal ultrasound in patients consuming &lt;50 g/d of alcohol. The statistical analysis was done with SPSS 17.0 (SPSS, Chicago, Illinois).</p>
<p>During the study period, 861 patients attended the office, of whom 454 (52.7%) had a negative serology for hepatotropic virus. Of these, 31 met the inclusion criteria, giving a prevalence of CHT of 6.8%. Most were men, the mean age was 45.7 years, and the predominant mode of transmission of the HIV infection was sexual. In all cases except 1, the elevation of the GPT was mild (&lt;3 times the normal values). The only parameter that differed between cases and controls was a greater body mass index in the cases. <xref ref-type="table" rid="table1-1545109711427606">Table 1</xref> shows the characteristics of the cases and controls. There were no differences in the use of ART. At least 1 other drug was being taken by 61.2% of the 31 cases and 48.3% of the controls. Lipid-lowering drugs were being taken by more of the cases than the controls (15 versus 7, <italic>P</italic> &lt; .05). An abdominal ultrasound was performed in 11 patients, 9 of whom showed signs of hepatic steatosis. No case had signs of portal hypertension. Liver stiffness could be assessed by elastometry (FibroScan) in 20. The mean stiffness was 5.9 Kps, with a range of 3.3 to 8.8 kPa. No patient had a liver biopsy. The most usual clinical diagnosis attributable to the CHT was ART toxicity, followed by NAFLD. Three patients were convalescing from hepatitis A virus (HAV) infection and 1 from secondary syphilis. Three patients required withdrawal of ART because of the CHT (<xref ref-type="table" rid="table1-1545109711427606">Table 1</xref>).</p>
<table-wrap id="table1-1545109711427606" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of the Cases and Controls</p>
</caption>
<graphic alternate-form-of="table1-1545109711427606" xlink:href="10.1177_1545109711427606-table1.tif"/>
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases (n = 31)</th>
<th>Controls (n = 31)</th>
<th>
<italic>P </italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>45.7</td>
<td>44.8</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Sex</td>
</tr>
<tr>
<td> Male</td>
<td>28</td>
<td>28</td>
<td>NS</td>
</tr>
<tr>
<td> Female</td>
<td>3</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">HIV risk</td>
</tr>
<tr>
<td> IDU</td>
<td>0</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td> HMX</td>
<td>25</td>
<td>19</td>
<td>NS</td>
</tr>
<tr>
<td> HTX</td>
<td>6</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>Smokers</td>
<td>12</td>
<td>14</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Alcohol consumption</td>
</tr>
<tr>
<td> &lt;50 g/d</td>
<td>31</td>
<td>30</td>
<td>NS</td>
</tr>
<tr>
<td> 50-100 g/d</td>
<td>0</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>History of liver disease</td>
<td>0</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>Cases of AIDS</td>
<td>7</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td>BMI, m<sup>2</sup>/kg</td>
<td>26.6</td>
<td>24.2</td>
<td>.02</td>
</tr>
<tr>
<td>Duration of infection, months</td>
<td>118.9</td>
<td>109.0</td>
<td>NS</td>
</tr>
<tr>
<td>Patients on ART</td>
<td>30</td>
<td>27</td>
<td>NS</td>
</tr>
<tr>
<td>VL &lt;50, copies/mL</td>
<td>30 (96.8%)</td>
<td>27 (87%)</td>
<td>NS</td>
</tr>
<tr>
<td>CD4, cells/mm<sup>3</sup>
</td>
<td>619.1</td>
<td>554.5</td>
<td>NS</td>
</tr>
<tr>
<td colspan="4">Clinical diagnosis</td>
</tr>
<tr>
<td> ART toxicity</td>
<td>
</td>
<td>14</td>
<td>
</td>
</tr>
<tr>
<td>  Nevirapine (NVP)</td>
<td>8<sup><xref ref-type="table-fn" rid="table-fn2-1545109711427606">a</xref></sup>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>  Efavirenz (EFV)</td>
<td>4<sup><xref ref-type="table-fn" rid="table-fn2-1545109711427606">a</xref></sup>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>  Didanosine (ddI)</td>
<td>2<sup><xref ref-type="table-fn" rid="table-fn3-1545109711427606">b</xref></sup>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Nonalcoholic fatty liver disease</td>
<td>
</td>
<td>9</td>
<td>
</td>
</tr>
<tr>
<td> Convalescence from syphilis</td>
<td>
</td>
<td>1</td>
<td>
</td>
</tr>
<tr>
<td> Convalescence from hepatitis A</td>
<td>
</td>
<td>3</td>
<td>
</td>
</tr>
<tr>
<td> Not diagnosed</td>
<td>
</td>
<td>4</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1545109711427606">
<p>Abbreviations: ART, antiretroviral therapy; VL, viral load; CD4, CD4 lymphocytes; IDU, injecting drug users; HMX, homosexual; HTX, heterosexual; BMI, body mass index.</p>
</fn>
<fn id="table-fn2-1545109711427606">
<p>
<sup>a</sup>In 1 patient, treatment was withdrawn because of increased liver stiffness measured by elastometry.</p>
</fn>
<fn id="table-fn3-1545109711427606">
<p>
<sup>b</sup>ddI was withdrawn in both the cases.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The prevalence of CHT in our series was much lower than the previously reported 11% to 15% values.<sup>
<xref ref-type="bibr" rid="bibr2-1545109711427606">2</xref><xref ref-type="bibr" rid="bibr3-1545109711427606"/>–<xref ref-type="bibr" rid="bibr4-1545109711427606">4</xref>
</sup> The prevalence of CHT in a large Swiss cohort was 13.2%, and it was associated with alcohol consumption, NAFLD, and the use of ART. The same study found the incidence to be 3.9 cases per 100 person-years.<sup>
<xref ref-type="bibr" rid="bibr4-1545109711427606">4</xref>
</sup> These differences are probably due to the methods used, the study population, and the differences at the time of the study. Of note, although, is the scarce clinical importance, with just 1 case of moderate CHT and few patients having to cease ART. On the other hand, although only just over one third of our patients had an ultrasound study, NAFLD can currently be considered one of the main causes of CHT in HIV-infected patients with no coinfection.<sup>
<xref ref-type="bibr" rid="bibr5-1545109711427606">5</xref>,<xref ref-type="bibr" rid="bibr6-1545109711427606">6</xref>
</sup> Hepatic steatosis is very usual in the general population, with very large differences between populations. It sometimes courses with CHT and can be associated with alcohol consumption, obesity, and metabolic disorders.<sup>
<xref ref-type="bibr" rid="bibr6-1545109711427606">6</xref>
</sup> Nonalcoholic fatty liver disease is very common in HIV-infected patients. Its origin is multifactorial and a sizeable percentage of patients do not have CHT.<sup>
<xref ref-type="bibr" rid="bibr4-1545109711427606">4</xref>,<xref ref-type="bibr" rid="bibr5-1545109711427606">5</xref>
</sup> The situation, although, may progress to steatohepatitis and hepatic fibrosis.<sup>
<xref ref-type="bibr" rid="bibr7-1545109711427606">7</xref>
</sup>
</p>
<p>Other causes of CHT in our series were sexually transmitted diseases, such as HAV and syphilis. The behavior of the former is usually benign, although normalization of transaminase levels is often slow, taking a mean of 170 days.<sup>
<xref ref-type="bibr" rid="bibr8-1545109711427606">8</xref>
</sup> The situation with syphilis is similar; liver involvement is common in early and secondary syphilis and normalization of transaminase levels can also take some time.<sup>
<xref ref-type="bibr" rid="bibr9-1545109711427606">9</xref>
</sup>
</p>
<p>In summary, CHT is uncommon in HIV-infected patients with no coinfection and its scarce clinical repercussion results in few patients having to cease ART. Nonetheless, the persistence of unexplained CHT is often associated with NAFLD and even fibrosis, thus necessitating diagnosis and treatment of modifiable factors due to the repercussions on long-term prognosis.<sup>
<xref ref-type="bibr" rid="bibr7-1545109711427606">7</xref>
</sup>
</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1545109711427606">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Thio</surname>
<given-names>CL</given-names>
</name>
</person-group>. <article-title>Liver disease in the HIV-infected individual</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2010</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1002</fpage>–<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr2-1545109711427606">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maida</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Núñez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ríos</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Severe liver disease associated with prolonged exposure to antiretroviral drugs</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2006</year>;<volume>42</volume>(<issue>2</issue>):<fpage>177</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr3-1545109711427606">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterling</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Snider</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections</article-title>. <source>Dig Dis Sci</source>. <year>2008</year>;<volume>53</volume>(<issue>5</issue>):<fpage>1375</fpage>–<lpage>1382</lpage>.</citation>
</ref>
<ref id="bibr4-1545109711427606">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ledergerber</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Battegay</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without Hepatitis B or C Virus co-infection</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>;<volume>50</volume>(<issue>4</issue>):<fpage>502</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr5-1545109711427606">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guaraldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Squillace</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stentarelli</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors</article-title>. <source>Clin Infect Dis</source>. <year>2008</year>;<volume>47</volume>(<issue>2</issue>):<fpage>250</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr6-1545109711427606">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crum-Cianflone</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dilay</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Nonalcoholic fatty liver disease among HIV-infected persons</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>50</volume>(<issue>5</issue>):<fpage>464</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr7-1545109711427606">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingiliz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Valantin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Duvivier</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy</article-title>. <source>Hepatology</source>. <year>2009</year>;<volume>49</volume>(<issue>2</issue>):<fpage>436</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr8-1545109711427606">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallego</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Robles</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of Acute Hepatitis A virus (HAV) infection on HIV viral load in HIV-infected patients and influence of HIV infection on acute HAV infection</article-title>. <source>J Int Assoc Physicians AIDS Care</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr9-1545109711427606">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crum-Cianflone</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weekes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bavaro</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Syphilitic hepatitis among HIV-infected patients</article-title>. <source>Int J STD AIDS</source>. <year>2009</year>;<volume>20</volume>(<issue>4</issue>):<fpage>278</fpage>–<lpage>284</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>